Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajnikant Patel

Interventional Cardiology Sun City West, AZ Medical Doctor

NPI 1841240835 CMS profile 219829

14420 W Meeker Blvd Ste 203, Sun City West, AZ 85375

Open in the dashboard

General payments

$1,313

36 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajnikant Patel of Sun City West, AZ is reported in the CMS Open Payments database as having received $1,313 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 14th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42 1
2024 General $128 4
2023 General $202 3
2022 General $386 12
2021 General $201 4
2020 General $38 2
2019 General $317 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajnikant Patel
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rajnikant Patel were reported at $42. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rajnikant Patel Interventional Cardiology median Middle half National median
2019 $317 $1,097 $329–$3,048 $163
2020 $38 $473 $161–$1,480 $114
2021 $201 $677 $233–$1,827 $132
2022 $386 $978 $333–$2,724 $149
2023 $202 $1,136 $382–$2,986 $160
2024 $128 $1,181 $395–$3,326 $164
2025 $42 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $785 16 payments
  2. HeartFlow, Inc. $187 2 payments
  3. Biosense Webster, Inc. $103 3 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $74 5 payments
  5. Bardy Diagnostics, Inc. $45 3 payments
  6. Abbott Laboratories $34 2 payments
  7. AstraZeneca Pharmaceuticals LP $21 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $19 1 payment
  9. Janssen Pharmaceuticals, Inc $16 1 payment
  10. Gilead Sciences, Inc. $15 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,313 36 payments
Products named General payments · program years 2019–2025
  1. General - Therapies $239 3 payments
  2. FFRct $187 2 payments
  3. General Therapies $126 2 payments
  4. GENERAL TACHY $113 1 payment
  5. Carto 3 $103 3 payments
  6. LifeVest $74 5 payments
  7. GENERAL BRADY $71 2 payments
  8. General - Tachy $50 1 payment
  9. Carnation Ambulatory Monitor $45 3 payments
  10. GENERAL PAIN MANAGEMENT $40 1 payment
  11. Other $223 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

61

Median for Interventional Cardiology: 2,236

Drug cost

$45,046

Median for Interventional Cardiology: $380,412

Branded share of claims

75.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 35 $44,645
Clopidogrel Clopidogrel Bisulfate Brand 11 $250
Atorvastatin Calcium Generic 15 $152

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$20,186

Medicare's payments for the services billed

Medicare patients

138

Average age 79

Services billed

260

68 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Chronic kidney disease 61%
Atrial fibrillation 59%
Arthritis 59%
Heart failure 50%
Diabetes 46%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record